Form 4 for DGX Quest Diagnostics
Accepted 2022-02-28 00:00:00 ET · period of report 2022-02-24 · accession 0001022079-22-000037 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2022-02-28 | 2022-02-24 | DGX | Davis J. E. | EVP-Gen. Diagnostics, CEO Elect | A - Grant | $0.00 | +9,787 | 57.3K | +21% | $0 |
| D | 2022-02-28 | 2022-02-24 | DGX | Davis J. E. | EVP-Gen. Diagnostics, CEO Elect | A - Grant | $0.00 | +47.5K | 47.5K | New | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2022-02-24 | A | A | 9,787 | $0.00 | 57,282 | D | — | — | (F1) Represents an award of restricted share units. |
| 2 | Derivative | Non-Qualifed Stock Option (right to buy) | 2022-02-24 | A | A | 47,529 | $0.00 | 47,529 | D | $127.73 · — to 2032-02-24 | 47,529 Common Stock | (F2) The options vest in three equal annual installments beginning on the first annual anniversary of the grant date. |